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| INTRODUC TI ON
Kidney transplant is the optimal treatment for patients with endstage renal disease. 1 However, pretransplant sensitization to donors, defined by the presence of circulating antibodies against human leukocyte antigens (HLAs), affects up to 43% of kidney transplant candidates on the transplant waitlist, and 23% of candidates are highly sensitized. 2 Although antibodies against HLAs may be present in the absence of a recognized sensitizing event, sensitization is most commonly induced after blood transfusions, pregnancy, and previous organ transplant. 3 The presence of preformed donor-specific antibodies (DSAs) is a major risk factor for the development of acute and chronic antibodymediated rejection (AMR) after kidney transplant. [4] [5] [6] The rate of acute AMR in kidney transplant recipients is reported to range between 20% and 40%, depending on multiple factors, [7] [8] [9] [10] [11] [12] and is associated with a >4-fold increase in the risk of graft loss compared with that in recipients not experiencing acute AMR. 13 In patients with preformed DSAs, acute AMR most commonly occurs within 2 to 3 months posttransplant 14, 15 but often occurs within the first 2 weeks. 16 Importantly, in addition to the risk of acute graft loss, patients who develop acute AMR are at a much greater risk of experiencing subsequent chronic AMR and late graft loss than are those who do not develop acute AMR. 4, 8, 11, 16, 17 Acute AMR occurs frequently in highly sensitized patients. As Because of the increased risk of developing acute AMR and the lack of a safe and effective treatment, such highly sensitized patients are frequently denied access to transplant. [18] [19] [20] These patients face prolonged wait times for transplant and are disproportionately represented on transplant waitlists. 20 As described by Jordan et al, the financial and emotional costs of maintaining highly sensitized transplant candidates on dialysis for years are extremely high, and these patients experience low quality of life and high mortality while waiting for transplant. 1, 2, 4, 20 Activation of the terminal complement system through the classic pathway is thought to be responsible for many of the manifestations of acute AMR. Terminal complement products damage the capillary vascular endothelium directly through the C5b9 membrane attack complex and indirectly initiate intense, local, acute inflammatory responses through the actions of C5a, the most potent anaphylatoxin in the body. 21 Eculizumab is a humanized monoclonal anti-C5 antibody that blocks the cleavage of complement component C5 and thereby inhibits the formation of terminal complement products. In a rat 21 Independent Consultant, Bellevue, Washington Correspondence Denis Glotz Email: denis.glotz@aphp.fr
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The presence of preformed donor-specific antibodies in transplant recipients increases the risk of acute antibody-mediated rejection (AMR). Results of an openlabel single-arm trial to evaluate the safety and efficacy of eculizumab in preventing acute AMR in recipients of deceased-donor kidney transplants with preformed donor-specific antibodies are reported. Participants received eculizumab as follows: 1200 mg immediately before reperfusion; 900 mg on posttransplant days 1, 7, 14, 21, and 28; and 1200 mg at weeks 5, 7, and 9. All patients received thymoglobulin induction therapy and standard maintenance immunosuppression including steroids. The primary end point was treatment failure rate, a composite of biopsy-proved grade II/III AMR (Banff 2007 criteria), graft loss, death, or loss to follow-up, within 9 weeks posttransplant. Eighty patients received transplants (48 women); the median age was 52 years (range 24-70 years). Observed treatment failure rate (8.8%) was significantly lower than expected for standard care (40%; P < .001). By 9 weeks, 3 of 80 patients had experienced AMR, and 4 of 80 had experienced graft loss. At 36 months, graft and patient survival rates were 83.4% and 91.5%, respectively. Eculizumab was well tolerated and no new safety concerns were identified. Eculizumab has the potential to provide prophylaxis against injury caused by acute AMR in such patients (EudraCT
2010-019631-35).
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clinical research/practice, complement biology, donors and donation: deceased, immunosuppressant-fusion proteins and monoclonal antibodies, kidney transplantation/ nephrology, rejection: antibody-mediated (ABMR), sensitization model of acute AMR after kidney transplant, terminal complement blockade preserved kidney allograft function and resulted in statistically significantly longer survival than in recipients who did not receive C5 blockade. 22 Clinical experience of using eculizumab for the treatment and prevention of acute AMR has had mixed results. [23] [24] [25] In a single-center study, eculizumab lowered the incidence of acute AMR in the first 3 months posttransplant in living-donor kidney recipients who were sensitized to their donor compared with a well-matched historical control group (7.7% [2 of 26] and 41.2% [21 of 51], respectively; P = .0031). 26 In a related study at the same center, there were no significant differences in C4d score, chronic glomerulopathy score, or peritubular capillaritis between the eculizumab and control groups at 12 months. 27 Together, these findings suggest that eculizumab may be clinically important in preventing acute AMR in the first days to weeks posttransplant.
The objective of this study was to evaluate the safety and efficacy of eculizumab for the prevention of acute AMR, and its effect on patient and graft survival, in individuals with preformed DSAs after deceased-donor kidney transplant.
| MATERIAL S AND ME THODS
| Study design
This was an open-label single-arm multicenter, international, phase 2 study to evaluate the safety and efficacy of eculizumab (Soliris gov identifier NCT01567085) was conducted in accordance with the Declaration of Helsinki, and the study protocol (C10-002) was approved by the appropriate ethics committee for each study site (Table S1 ). Participants provided written informed consent before study entry. The study was sponsored by Alexion Pharmaceuticals.
The study design is illustrated in Figure 1 . 
| Study population
Patients were recruited from 15 sites in 6 countries across Europe and Australia (Table S2) . Patients aged 18 years or older were eligible for inclusion if they had stage V chronic kidney disease and were identified to receive a kidney transplant from a deceased donor to whom they were sensitized. Eligible patients had a history of previous exposure to HLA, and were required to have a negative complement-dependent cytotoxicity (CDC) assay at the time of transplant plus 1 or more of the following: historical positive CDC crossmatch, BFXM or TFXM of ≥300 and ≤500 mcs, 7 or DSAs identified by single antigen bead assay (Luminex Labscreen assay) with a single mean fluorescence intensity >3000 at <3 months pretransplant. 
| Primary efficacy end point
The primary efficacy end point was the treatment failure rate within 
| Patient and graft survival
Graft and patient survival at 6 and 12 months posttransplant were secondary end points for this study; 36-month survival was also re- 
| Safety end points
Safety end points were evaluated throughout the study and at up to 36 months posttransplant. Safety assessments included recording and monitoring all treatment-emergent adverse events (TEAEs) and serious adverse events. The cumulative incidence of biopsy-proved acute cellular rejection was recorded.
| Statistical methods
The null hypothesis was that the true treatment failure rate within the first 9 weeks posttransplant with standard of care in this population was expected to be 40%. This failure rate was derived from a pooled analysis of AMR data obtained from the literature: [8] [9] [10] [11] [12] using a random-effects model, the background rate of AMR was calculated to be 34.8% (random-effects confidence interval [CI] 26.3% to 44.3%). This was conservatively increased to the expected treatment failure rate of 40% to account for the other end point components (graft loss, death, and loss to follow-up, which may be unrelated to AMR). The null hypothesis was tested by using the exact binomial test. Sample size was determined based on a 2-sided 5% level of significance, the null hypothesis, and an alternative hypothesis of composite end point treatment failure rate of 20% at 9 weeks posttransplant with eculizumab. The sample size of 80 gave a power of >90%. All statistical analyses were performed by using the SAS statistical software system version 9.4 (SAS Institute, Cary, NC).
| Analyses
Efficacy and safety analyses were conducted by using data from all enrolled patients who received a deceased-donor kidney transplant and at least 1 dose of eculizumab. Owing to the small number of patients expected to enroll at each center, all summaries and analyses were performed by using data pooled across centers.
| RE SULTS
| Patient disposition and characteristics
Eighty-six patients were screened for study inclusion; 80 eligible patients were enrolled and received a deceased-donor kidney plus at least 1 dose of eculizumab. Seventy-six patients completed all 9 weeks of the eculizumab treatment regimen (Figure 1 ). 
| Treatment outcomes
At 9 weeks posttransplant, treatment failure rate (with AMR determined by central pathology) was 8.8%, which was significantly lower than the expected failure rate of 40% for the standard of care in this population (exact binomial 95% CI 3.6% to 17.2%; P < .001).
Treatment failure rate at 9 weeks posttransplant with AMR determined by local pathology was 13.8%, which was slightly higher than the failure rate determined by central pathology but still significantly lower than the expected failure rate of 40% for this population (95% CI 7.1% to 23.3%; P < .001). At 12 months posttransplant, the treatment failure rates determined by central and local pathology increased to 18.8% and 26.3%, respectively ( Table 3 ). these numbers increased to 5 (6.3%) and 12 (15.0%), respectively (Table 3 ). All cases of AMR were grade II.
| Patient and graft survival
The number of graft losses increased from 4 (5.0%) by 9 weeks to 10 (12.5%) by 12 months (Table 3) . Eight of these 10 graft losses occurred at 2 sites. The 4 graft losses that occurred by week 9 resulted from nonimmunologic processes: primary nonfunction (with no initial renal output in 2 patients, due to technical problems according to the principal investigators) and renal artery thrombosis (by study day 1 in 2 patients). The 6 graft losses that occurred between 9 weeks and 12 months included 3 cases of chronic rejection, 2 cases of acute AMR (1 with features of thrombotic microangiopathy), and 1 case of acute cellular rejection (Table S4 ). During the 3-year study period, there were 14 graft losses. The 4 graft losses that occurred between 12 and 36 months were attributed to chronic rejection (chronic AMR in 3 cases [only preceded by biopsy-proved acute AMR in 1 case] and chronic T cell-mediated rejection in 1 case). At 12 and 36 months, patient survival was 97.5%, and 91.5%, respectively, and graft survival was 87.4% and 83.4%, respectively (Figures 2 and S1 ).
| Other functional outcomes
The mean cumulative number of PP treatments per patient over 12 months was 2. Table S5 . SCr levels that were >30% above nadir for a median of 325.5 days were observed in 2 patients after a diagnosis of acute AMR. Protocol-specified biopsy specimens at 12 months revealed chronic AMR in 1 patient and chronic T cell-mediated rejection in 1 patient (Table S6 ).
| Safety assessments
In total, 95.0% of patients (76 of 80) received the planned 9 doses of eculizumab; administration was ceased prematurely in 4 patients (5.0%) due to graft loss or death. Twelve patients received additional doses of eculizumab after 9 weeks to treat AMR. Complete 12-and 36-month data were obtained for 69 and 60 patients, respectively (Figure 1 ).
TEAEs occurring throughout the study are presented in Tables 5 and   S7 . All patients experienced at least 1 TEAE. The most frequent TEAEs were anemia (63.8%), diarrhea (47.5%), and transplant rejection (including a range of immunological biopsy findings; 43.8%). During the study, 70 patients (87.5%) experienced a serious adverse event: 5 patients (6.3%) experienced a drug-related serious adverse event, and 65 patients (81.3%) experienced a confirmed, clinically significant infection (Table 5) . At 12 and 36 months, 3 and 5 patients, respectively, had experienced biopsy-proved acute cellular rejection (Table 6 ).
| D ISCUSS I ON
There is currently no definitive therapy to prevent reliably the development of acute AMR in kidney transplant recipients who are sensitized to their deceased donors. In candidates for transplant who are sensitized to their living donors, desensitization therapy is commonly used pretransplant. However, this approach cannot be used for candidates waiting to receive a deceased-donor kidney as neither organ availability nor DSA status can be known far enough in advance of transplant to allow for desensitization therapy. Consequently, transplant is frequently considered to be contraindicated for patients highly sensitized to potential deceased donors, in order to avoid AMR. DSA, donor-specific antibody; MFI, mean fluorescence intensity. a Central laboratory data were confirmatory only and are included for consistency; local laboratory data and historical data were used to evaluate patient eligibility; N = 79 for this variable. b Eight patients had no DSAs at transplant but were included in the study because they had a historical positive crossmatch.
The objective was to determine the efficacy and safety of eculizumab to prevent acute AMR from occurring in this unique patient population.
In this study, the proportion of recipients who experienced treatment failure within 9 weeks of kidney transplant (8.8%) was significantly lower than the expected rate of treatment failure (40%) for patients receiving standard of care according to the null hypothesis derived from published data. As expected, the incidence of AMR decreased after the first 9 weeks. Interestingly, the treatment failure rate reported here in deceased-donor kidney recipients is similar to that observed in the eculizumab arm of a phase 2, randomized controlled study in living-donor transplant recipients (9.8%).
30
Graft loss was a significant contributor to the outcome of this study. In total, 14 patients lost their transplanted kidneys during the study. It is noteworthy that 9 of these graft losses occurred at 2 institutions, which may have influenced the overall interpretation of the data. Nonimmunological causes of graft loss (primary nonfunction attributed to technical complications by the principal investigator in 2 cases and renal artery thrombosis in 2 cases) at these 2 institutions accounted for all 4 treatment failures that occurred within the first 9 weeks after transplant. Only 2 of the 10 graft losses that occurred after week 9 were due to acute AMR. Patient and graft survival rates after 3 years (91.5% and 83.4%, respectively) were favorable considering the long duration of pretransplant dialysis in these patients, which is known to be a strong risk factor for poor renal transplant outcomes. 31 Key secondary outcomes (requirement of dialysis, splenectomy, or PP, or incidence of cellular rejection) were consistent with results expected in nonsensitized patients.
The incidence of adverse events, including infections, was consistent with the expected incidence for a highly sensitized population of patients with stage V chronic kidney disease receiving high doses of immunosuppressant agents. [32] [33] [34] [35] [36] [37] [38] [39] No new safety signals for eculizumab were detected. The safety profile was consistent with that reported for eculizumab's use for approved indications, including atypical hemolytic uremic syndrome 40, 41 and paroxysmal nocturnal hemoglobinuria. Local pathology, used to guide patient management and therefore including clinically relevant acute AMR of any stage, reported a higher rate of AMR diagnosis, which was based on both biopsy and clinical information. Discordance in Banff classification between pathologists has been reported previously 45 and was investigated in a study of eculizumab in living-donor kidney transplant recipients. 30 In addition, differences in patient populations and deceased-donor transplant practices between transplant centers may have influenced interpretation of the data. The rate of early nonimmunologic graft loss at 2 transplant centers may have reduced the apparent effectiveness of eculizumab in this study. Further, these highly sensitized patients had a long median time on dialysis before transplant, exceeding 10 years, which put them at higher than average risk for poor transplant outcomes, including those that constituted the primary end point. 46, 47 Considering this, the rate of successful transplant among them is notable.
It is unlikely that the investigator community would be willing to a Drug-related events are defined as those judged by the investigator to be possibly, probably, or definitely related to the study drug. Events that are judged by the investigator to be unlikely to be related or unrelated to study drug were defined as not drug-related events. b Results include clinically significant for cytomegalovirus, BK virus, and encapsulated bacterial, fungal, and aspergillus infection confirmed by culture, biopsy, genomic, or serologic findings that required hospitalization or anti-infective treatment, or otherwise deemed significant by the investigator.
TA B L E 6 Cumulative incidence of biopsy-proved acute cellular rejection based on local pathology analysis plan and protocol) pertaining to this study. Further details regarding data availability, instructions for requesting information and our data disclosure policy will be available on the Alexion.com website (http://alexi on.com/resea rch-devel opment).
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